Finance Watch: Have Investors Reached IPO Fatigue?
Only Two Of Six Newly Public Companies Trade Above IPO Price
Executive Summary
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
You may also be interested in...
Finance Watch: Kronos Bio IPO Raises $250m To Fund Novel Cancer Drugs
Initial public offerings by Norbert Bischofberger’s start-up as well as Spruce Biosciences and Shattuck Labs bring the US total to 65 in 2020. Also, the pipeline of health care SPACs is growing, Everest and Genor went public in Hong Kong, Idorsia leads recent follow-on offerings and Corbus cuts jobs.
Deal Watch: Private Equity-Backed Covis Bids To Buy Troubled AMAG
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
On The Docket: Recent Submissions For US FDA Approval
Round-up of late summer applications recently submitted to US FDA, adapted from the Pink Sheet FDA Performance Tracker's User Fee Goal Dates chart.
Need a specific report? 1000+ reports available
Buy Reports